BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 17267906)

  • 21. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
    Schnittger S; Bacher U; Haferlach C; Geer T; Müller P; Mittermüller J; Petrides P; Schlag R; Sandner R; Selbach J; Slawik HR; Tessen HW; Wehmeyer J; Kern W; Haferlach T
    Haematologica; 2009 Mar; 94(3):414-8. PubMed ID: 19252176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.
    Li S; Kralovics R; De Libero G; Theocharides A; Gisslinger H; Skoda RC
    Blood; 2008 Apr; 111(7):3863-6. PubMed ID: 18195094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
    Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
    Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
    Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
    Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
    Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
    Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
    Passamonti F; Elena C; Schnittger S; Skoda RC; Green AR; Girodon F; Kiladjian JJ; McMullin MF; Ruggeri M; Besses C; Vannucchi AM; Lippert E; Gisslinger H; Rumi E; Lehmann T; Ortmann CA; Pietra D; Pascutto C; Haferlach T; Cazzola M
    Blood; 2011 Mar; 117(10):2813-6. PubMed ID: 21224469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis.
    Cazzola M
    Haematologica; 2007 Dec; 92(12):1585-9. PubMed ID: 18055979
    [No Abstract]   [Full Text] [Related]  

  • 30. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
    Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
    Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance.
    Park CH; Lee KO; Jang JH; Jung CW; Kim JW; Kim SH; Kim HJ
    J Clin Pathol; 2016 Aug; 69(8):737-41. PubMed ID: 27198504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycythemia vera: the current status of preclinical models and therapeutic targets.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
    Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W; Constantinescu SN
    Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2 in myeloproliferative disorders is not just another kinase.
    Tefferi A; Gilliland DG
    Cell Cycle; 2005 Aug; 4(8):1053-6. PubMed ID: 15970705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fast and reliable mutation detection of the complete exon 11-15 JAK2 coding region using non-isotopic RNase cleavage assay (NIRCA).
    Kambas K; Mitroulis I; Kourtzelis I; Chrysanthopoulou A; Speletas M; Ritis K
    Eur J Haematol; 2009 Sep; 83(3):215-9. PubMed ID: 19500139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
    Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
    Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F
    Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.